Clinical Trial

A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 24, 2026 (before its estimated July 21, 2026 completion). Its status may not reflect the trial's current state.
Summary
Researchers are looking for new treatments for people living with HIV-1(Human Immunodeficiency Virus Type 1). HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. HIV-1 treatments, called ART (antiretroviral therapy), involve taking medicines to lower the amount of HIV-1 virus in the body. Standard ART may include Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) and Dolutegravir (DTG). MK-4646 is a trial medicine designed to treat HIV-1. Before giving a trial medicine to people with a health condition, researchers first do trials in healthy people. The goals of this study are to learn: * If taking MK 4646 together with BIC/FTC/TAF or DTG changes the amount of these ARTs in the blood over time. * About the safety of MK-4646 and if people tolerate it. Tolerate means participants will receive treatment in the trial unless they need to stop it due to health problems.
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-25
critical Recruitment opened 2026-05-15
critical Primary endpoint(s) modified 2026-05-07
Trial Details
NCT Number NCT07532304
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Healthy
Enrollment 16 participants
Start Date 2026-05-11
Primary Completion 2026-07-21 (estimated)
Study Completion 2026-07-21 (estimated)
Updated on ClinicalTrials.gov 2026-06-24